Elisabeth Schorb

[Fernando Martín Moro @Fer_martinmoro]

@CwynKate and A Ferreri presenting the @EHA_Hematology - @myESMO Guidelines on primary CNS #lymphoma at #EHA2024 🧠

[ESMO - Eur. Oncology @myESMO]

New📢Primary Central Nervous System #Lymphomas: @EHA_Hematology–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Covering clinical, imaging & pathological diagnosis, staging & risk assessment, tx, & algorithms for first-line & salvage treatments. https://t.co/A0TA3Wie11

@CwynKate @DrChrisPFox @LizSchorb @MJerkeman #lymsm

[The Lancet Haematology @TheLancetHaem]

@LizSchorb You can read the report on the MARTA trial here https://t.co/lqCbA9gye3

Also, the linked comment by Elizabeth H Phillips & @CwynKate #lymsm https://t.co/EMREk8KdgU

[The Lancet Haematology @TheLancetHaem]

🎧NEW podcast: @LizSchorb on the MARTA phase 2 trial testing high-dose chemotherapy and autologous haematopoietic stem-cell transplantation in older, fit patients with primary diffuse large B-cell CNS lymphoma #lymsm https://t.co/dVoMJaYPFw

[Kate Cwynarski @CwynKate]

@LizSchorb @TheLancetHaem @EKFStiftung & our commentary - pleasure working with @phillibeth & a credit to @LizSchorb @GeraldIllerhaus & all co-authors @TheLancetHaem #PCNSL
https://t.co/wRu29nxjI5

[Elisabeth Schorb @LizSchorb]

Delighted to share the results of our MARTA trial, just published in @TheLancetHaem. A collaborative effort of the German PCNSL Study Group. We are deeply thankful for the support of all collaborators and @EKFStiftung
https://t.co/JeZYLjOsCE

[Women in Lymphoma - [email protected] @WomenInLymphoma]

6/10 invited manuscript by @WomenInLymphoma
for #HematologicalOncology @icmlugano

"Central nervous system lymphomas—Assessment and treatment and prevention of central nervous system relapse" https://t.co/LiArW5khs9
#lymsm #lymphoma #CellularTherapy
@lymphomaOz

[Chris Fox @ProfChrisPFox]

Potentially practice-changing Ph3 RCT for MATRix-eligible pts with newly dx PCNSL. Great to collaborate with 🇩🇪 colleagues @LizSchorb @GeraldIllerhaus

@CRUKresearch @SU2CUK funded incl translational science @Jessica_Okosun & imaging @NottmBRCMRI
@ResearchNuh

[Kate Cwynarski @CwynKate]

@DrAEvens @majorajay Really important data @DrAEvens & great 🇺🇸 collaboration 👏 We showed similar findings and helpful to have RWE data in #PCNSL >60yrs.
We ⬆️ consider TT-ASCT >70yrs & exciting to hear MARTA trial @LizSchorb @GeraldIllerhaus #ASH2022
https://t.co/bbXOwSdPBH

[Krishna Komanduri, MD, FASTCT @drkomanduri]

Remarkable results and (for a change) a reaffirmed role for autoSCT in primary CNS #lymphoma.

[Kate Cwynarski @CwynKate]

#ASH22 Late Breaking Abstract @GILLI_1969 presents IELSG43 randomised trial: impressive data in #PCNSL for consolidation TT-based ASCT after MATRix <70y
3 year OS 86%
Credit to all the investigators for addressing this important question ⁦@LizSchorb⁩ #IELSG #AndresFerreri

[Chris Fox @ProfChrisPFox]

@GeraldIllerhaus IELSG43 data - underscoring superiority of TT/BCNU ASCT as highly effective consolidation following MATRix remission induction. Key unmet need remains wrt early events & failure to reach ASCT; 🇩🇪 🏴󠁧󠁢󠁥󠁮󠁧󠁿 🇮🇹 OptiMATE Ph3 aiming to optimise @LizSchorb @CwynKate

[Kate Cwynarski @CwynKate]

Tues Dec 13 #ASH2022 late breaking abstract 👏
Effects on Survival of Non-Myeloabl chemo c.f. HD-Chemo follow by HDC-ASCT As Consolidatn in #PCNSL Results of International Randomized Phase III Trial (MATRix/IELSG43) ⁦@Schorb_Liz⁩ ⁦@GILLI_1969⁩ https://t.co/GMvit7w8pH

[Nico Gagelmann @NicoGagelmann]

ASCT for lymphoma #ASH22 part 1:
-feasible in selected elderly patients with newly diagnosed primary CNS lymphoma with survival rates comparable to those of younger cohorts
-non-relapse mortality remains a major challenge in this vulnerable population https://t.co/noQvMYzV8o
/5

[Women in Lymphoma - [email protected] @WomenInLymphoma]

A great collaboration in EU is going on for a large randomized trial for treatment of CNS lymphoma in the elderly!
@WomenInLymphoma WiLing Wednesday on treatment of elderly PCNS and side effects of radiation #lymsm @Schorb_Liz

[Uniklinik Freiburg @Uniklinik_Fr]

Internationale #Studie unter Leitung der @Uniklinik_Fr mit 3,1 Mio. € gefördert. Diese soll Heilungsaussichten bei aggressiven #Lymphomen im #Gehirn verbessern, welche überwiegend bei älteren Personen auftreten und unbehandelt innerhalb von wenigen Monaten zum Tod führen.

[Elisabeth Schorb @LizSchorb]

@tobyeyre82 @MartinezCalleMD @CwynKate Always a pleasure to work with our fantastic colleagues from the UK

[BMFTR @bmftr_bund]

Heute ist #Welthirntumortag. Allein in 🇩🇪 erkranken jährl. mehr als 7.000 Menschen daran. Die Studie PRIMA-CNS @Uniklinik_Fr will 2 bestehende Therapieansätze bei #Hirntumoren miteinander vergleichen, um neuen Standard in Patientenversorgung zu erreichen. https://t.co/oCBtUmgwwi